Journal article

Predictors of Institutionalization in Dementia: A Three Year Longitudinal Study

Henry Brodaty, Michael H Connors, Jing Xu, Michael Woodward, David Ames

Journal of Alzheimer's Disease | IOS PRESS | Published : 2014

University of Melbourne Researchers

Grants

Funding Acknowledgements

The Dementia Collaborative Research Centre is funded by the National Health and Medical Research Council. We thank the staff at nine sites who collected data and the patients and caregivers who supported the study.The study was funded in part by Janssen-Cilag Pty Limited. HB and MW have worked on drug trials for patients with MCI and AD sponsored by major pharmaceutical companies including Eisai Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline, H Lundbeck A/S, Janssen-Cilag Pty Limited, Medivation Inc., Novartis Pharmaceuticals, Nutricia, Pfizer Inc., Prana Biotechnology Limited, Sanofi-Aventis, Tau Rx, Voyager Pharmaceutical Corporation, and Wyeth Limited. MW has also worked/is working on trials sponsored by Servier, Forest, Merck Sharp and Dohme, Takeda and the Buck Institute. HB has also been a consultant, advisory board member, and sponsored speaker for Baxter, H Lundbeck A/S, Janssen-Cilag Pty Limited, Medivation Inc., Novartis Pharmaceuticals, Pfizer Inc., Prana Biotechnology Limited, Voyager Pharmaceutical Corporation, and Wyeth Limited. MW has also been a consultant and speaker for these companies as well as bioCSL, Prana Biotechnology, Eli Lilly and Company and Merck Sharp and Dohme. DA has served as a paid consultant to Janssen-Cilag and has also received payment for consultancies from Baxter, Eli Lilly, Lundbeck, Prana, Pfizer, and Novartis.